alexa Is Body Weight Loss a Harbinger of Methamphetamine-induced Neurotoxicity? | Open Access Journals
ISSN: 2155-6105
Journal of Addiction Research & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Is Body Weight Loss a Harbinger of Methamphetamine-induced Neurotoxicity?

Dean E Dluzen1*, Altaf S Darvesh2 and Werner J Geldenhuys3

1Department of Anatomy and Neurobiology, Department of Pharmaceutical Sciences, Northeast Ohio Medical University, USA

2Department of Pharmaceutical Sciences, Department of Psychiatry, Northeast Ohio Medical University, USA

3Department of Pharmaceutical Sciences, Northeast Ohio Medical University, USA

*Corresponding Author:
Dean Dluzen
Department of Anatomy and Neurobiology
Northeast Ohio Medical University
4209 State Route 44, P. O. Box 95
Rootstown, OH, USA
Tel: 330-325-6300
Fax: 330-325-5913
E-mail: [email protected]

Received October 17, 2012; Accepted November 22, 2012; Published November 29, 2012

Citation: Dluzen DE, Darvesh AS, Geldenhuys WJ (2012) Is Body Weight Loss a Harbinger of Methamphetamine-induced Neurotoxicity? J Addict Res Ther 3:138. doi:10.4172/2155-6105.1000138

Copyright: © 2012 Dluzen DE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Addiction Research & Therapy

Methamphetamine (MA) is a drug of abuse of societal concern. Euphoria, increased energy/alertness and enhanced libido all contribute to the appeal, and therefore, abuse of this psychostimulant. Weight loss represents still another attribute of MA as indicated in both human [1-4] and animal [5,6] studies. In fact, weight loss has been reported as a reason for MA use [7-9] and MA under the trademark name Desoxyn, has been approved for use clinically in the treatment of exogenous obesity, as well as for ADHD and narcolepsy [10].

In animal studies, MA has served as an agent to induce neurotoxicity within the Nigrostriatal Dopaminergic (NSDA) system, and thus a means to study conditions that modulate this neurotoxicity. For example, sex, hormonal factors and adrenergic blockers all affect the degree of MAinduced neurotoxicity [11-16]. A summary of the pair wise differences in MA-induced neurotoxicity (dorsal striatal dopamine depletion) for these three different factors, along with the corresponding changes in body weight to MA is illustrated in panels A-C of the Figure 1. In all three situations, conditions showing greater amounts of dopamine depletion (A-males versus females, B-testosterone (TP) versus sesame oil vehicle treated controls, C-Propranolol (PROP) versus Prazosin (PRAZ)) are associated with the greater amounts of body weight reductions.

addiction-research-experimental-striatal-dopamine

Figure 1: Percent reductions in dorsal striatal dopamine concentrations (pg of dopamine/mg of tissue weight as analyzed with HPLC-EC) versus respective vehicle-treated controls (•—•) and changes in body weights (gm) calculated as differences between weights immediately prior to neurotoxin administration versus that obtained at euthanasia (5-7 days post-neurotoxin) (o----o)-Mean ± SEM. Adult mice (CD-1, Panels A-C; C57/Bl, Panel D) were treated with a single ip injection of methamphetamine at 40 mg/kg (panels A-C) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at 10 mg/kg administered ip at 2 h intervals×4 (panel D). For all methamphetamine-treated conditions greater amounts of dorsal striatal dopamine depletion (A-males versus females, B-testosterone (TP- 5 μg in sesame oil, sc) versus sesame oil treated controls, C-propranolol (PROP-10 mg/kg in saline, ip) versus prazos in (PRAZ - 2 mg/kg in saline, ip)) are associated with greater reductions in body weights. While a very similar profile of reductions in dorsal striatal dopamine between male and female mice is observed in response to MPTP (•—• panels D versus A), no sex differences in body weights are present to MPTP treatment, unlike that obtained for MA (o----o panels D versus A). With the exception of body weights for females versus males in response to MPTP (panel D), all respective pair wise comparisons (independent group t-tests) represent statistically significant differences (p<0.05). All data presented represent studies that had been approved by the IACUC at the Northeast Ohio Medical University (NEOMED). Data were compiled from the following sources: Panel A [14]; Panel B [13,15]; Panel C [16]; Panel D [21].

A cursory and seemingly obvious conclusion would be that the greater extent of neurotoxicity produces a corresponding greater degree of generalized malaise, as indicated by body weights. The data presented in panel D of the Figure 1 suggest that this may not necessarily be the case. Here are presented results obtained using a similar sex-differences protocol as that presented in panel A, however, with NSDA neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). While nearly identical dorsal striatal dopamine reductions are obtained with MA and MPTP (A versus D), the corresponding sex differences in body weight present to MA, are completely absent with MPTP (A versus D). Such results suggest that sex differences in response to neurotoxins targeting the NSDA system do not inescapably generate identical changes in body weights. Rather, body weight reductions following MA treatment appear to be closely associated with the degree of NSDA loss and are specific for MA-induced NSDA neurotoxicity.

Confirmation or refutation of this intriguing relationship awaits further investigation involving formal experiments on dose-response, time-course, cross-species analyses and food restriction/palatability. Moreover, differences in MA regimes between the mouse models as described above and the clinical/street use of this drug also warrant consideration in evaluating this relationship. While remaining cognizant of these limitations, data derived from these animal experiments have served as relatively valid and reliable models for indices of effects in humans. Women show less toxicity [17] and diminished dopamine responses [18] to MA/amphetamine as compared with men, which is similar to that of results obtained with mice [19,20]. Of particular relevance to the present report, are the findings indicating that weight loss is a pervasive characteristic of MA, as seen in mice and humans [1-6]. Given that one of the presumptive “benefits” of MA, both as a street drug and for clinical application is its capacity for weight reduction, an important implication for this relationship between body weight and neurotoxicity as described above is the potential for unwitting damage to the NSDA system as associated with the weight reduction resulting from MA. Rephrased as a question: Is Body Weight Loss a Harbinger of Methamphetamine-induced Neurotoxicity?

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11631
  • [From(publication date):
    December-2012 - Nov 20, 2017]
  • Breakdown by view type
  • HTML page views : 7856
  • PDF downloads : 3775
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords